Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.51 and traded as high as $0.73. Xtant Medical shares last traded at $0.69, with a volume of 126,832 shares changing hands.
Xtant Medical Stock Down 1.7%
The company has a market capitalization of $95.93 million, a P/E ratio of -5.31 and a beta of 0.35. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. The firm's fifty day moving average is $0.49 and its 200-day moving average is $0.51.
Institutional Investors Weigh In On Xtant Medical
A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC increased its holdings in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 798,033 shares of the medical device company's stock after buying an additional 103,825 shares during the period. Renaissance Technologies LLC owned about 0.57% of Xtant Medical worth $354,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 69.33% of the company's stock.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
